Lintuzumab ELISA Kit

Catalog No.

KDD37501

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD33 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Lintuzumab in the sample competitively binds to the pre-coated protein with biotin-labeled Lintuzumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Lintuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Lintuzumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.13 - 5,000 ng/mL

Sensitivity

39.06 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	2593.7	680.7	164.3	2490.9	699.3	253.3
Standard deviation	293.3	87.3	23.5	223.8	132.2	37.2
CV (%)	11.3	12.8	14.3	9.0	18.9	14.7

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3

Background

Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. An initial phase I dose-escalation trial demonstrated that for a single infusion of [225Ac]Ac-lintuzumab in patients with relapsed or refractory acute myeloid leukemia, the maximum tolerated dose (MTD) was determined to be 111 kBq/kg with antileukemic activity across all dose levels. No evidence of radiation-induced nephrotoxicity was seen. Peripheral blasts were eliminated in 63% of the patients at doses of >37 kBq/kg. Bone marrow blast reduction was observed in 67% of patients. Subsequently, a multicenter phase I dose-escalation trial was conducted to define MTD, toxicity, and response rate of fractionated-dose [225Ac]Ac-lintuzumab when combined with low-dose cytarabine (LDAC) in older patients with untreated AML who were not candidates for intensive chemotherapy.

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia., PMID:39955432

89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia., PMID:38987489

Developing a membrane-proximal CD33-targeting CAR T cell., PMID:38772686

Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window., PMID:38561023

HuM195 and its single-chain variable fragment increase Aβ phagocytosis in microglia via elimination of CD33 inhibitory signaling., PMID:38383769

In Vitro and In Vivo Characterization of 89Zirconium-Labeled Lintuzumab Molecule., PMID:36235126

Where do we stand with radioimmunotherapy for acute myeloid leukemia?, PMID:35350938

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab., PMID:35247915

Radiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides., PMID:34750237

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design., PMID:34531250

225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models., PMID:33347715

CD33-Targeted Therapies: Beating the Disease or Beaten to Death?, PMID:32875599

Targeted Alpha-Particle Therapy for Hematologic Malignancies., PMID:32172800

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A., PMID:31439003

Targeted Alpha-Particle Therapy for Hematologic Malignancies., PMID:31253514

Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies., PMID:29793418

Investigational CD33-targeted therapeutics for acute myeloid leukemia., PMID:29534618

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors., PMID:29206680

Advances in immunotherapy for pediatric acute myeloid leukemia., PMID:28945115

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML., PMID:28321813

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia., PMID:27535972

ADCs Show Promise in Leukemias., PMID:27388473

Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia., PMID:25762156

Novel drugs for older patients with acute myeloid leukemia., PMID:25142817

Targeted alpha-particle immunotherapy for acute myeloid leukemia., PMID:24857092

New agents: great expectations not realized., PMID:24309529

Precision 're'arming of CD33 antibodies., PMID:23970353

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML., PMID:23770776

Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands., PMID:23014531

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia., PMID:22801961

What happened to anti-CD33 therapy for acute myeloid leukemia?, PMID:22109628

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia., PMID:20858843

5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia., PMID:20495353

Gateways to clinical trials., PMID:20094643

Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia., PMID:20065652

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial., PMID:19557623

Newer monoclonal antibodies for hematological malignancies., PMID:18565392

Antibody therapy for acute myeloid leukemia., PMID:18381105

Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia., PMID:18300754

Ab therapy of AML: native anti-CD33 Ab and drug conjugates., PMID:17917880

Gateways to clinical trials., PMID:16395422

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia., PMID:15961759

Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor., PMID:15661266

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates., PMID:14734685

Gateways to clinical trials., PMID:12949633

Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia., PMID:12141950

Document Download

Lintuzumab ELISA Kit.pdf